355 related articles for article (PubMed ID: 21284696)
1. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Praharaj SK; Jana AK; Goyal N; Sinha VK
Br J Clin Pharmacol; 2011 Mar; 71(3):377-82. PubMed ID: 21284696
[TBL] [Abstract][Full Text] [Related]
2. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
3. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
4. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
5. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
[TBL] [Abstract][Full Text] [Related]
6. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Citrome L; Holt RI; Walker DJ; Hoffmann VP
Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
[TBL] [Abstract][Full Text] [Related]
7. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
[TBL] [Abstract][Full Text] [Related]
8. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
[TBL] [Abstract][Full Text] [Related]
9. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
10. A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.
Rado J; von Ammon Cavanaugh S
J Clin Psychopharmacol; 2016 Apr; 36(2):163-8. PubMed ID: 26872112
[TBL] [Abstract][Full Text] [Related]
11. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Wang M; Tong JH; Zhu G; Liang GM; Yan HF; Wang XZ
Schizophr Res; 2012 Jun; 138(1):54-7. PubMed ID: 22398127
[TBL] [Abstract][Full Text] [Related]
12. Weight gain during treatment of bipolar I patients with olanzapine.
Hennen J; Perlis RH; Sachs G; Tohen M; Baldessarini RJ
J Clin Psychiatry; 2004 Dec; 65(12):1679-87. PubMed ID: 15641874
[TBL] [Abstract][Full Text] [Related]
13. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
Siskind DJ; Leung J; Russell AW; Wysoczanski D; Kisely S
PLoS One; 2016; 11(6):e0156208. PubMed ID: 27304831
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
15. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
16. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Wu RR; Jin H; Gao K; Twamley EW; Ou JJ; Shao P; Wang J; Guo XF; Davis JM; Chan PK; Zhao JP
Am J Psychiatry; 2012 Aug; 169(8):813-21. PubMed ID: 22711171
[TBL] [Abstract][Full Text] [Related]
17. Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Mostafavi SA; Solhi M; Mohammadi MR; Akhondzadeh S
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):440-444. PubMed ID: 28339282
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
19. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
20. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Hoffmann VP; Case M; Jacobson JG
J Clin Psychiatry; 2012 Feb; 73(2):216-23. PubMed ID: 21672497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
